Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

Hallym University Medical Center38 enrolled

Overview

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Interventions

intravitreal injectionPROCEDURE

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion Exclusion Criteria: * previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset * Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders * neovascularization on the disc or elsewhere or rubeosis

Locations (1)

keoung ik Na

Chuncheon, anyang, South Korea

Outcomes

Primary Outcomes

best corrected visual acuity

Time frame: baseline, 1 month, 2 months, 3 months, 6 months, 12 months

Secondary Outcomes

central macular thickness by optical coherence tomography

Time frame: baseline, 1 month, 2 months, 3 months, 6 months 12months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.